Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months

NCT00649883 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Influenza Trivalent Inactivated vaccines Novartis
BIOLOGICAL: Influenza Trivalent Inactivated vaccines

Sponsor

Novartis

Collaborators

[object Object]